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background: The aim of the study was to investigate 4-year outcomes and predictors of adverse outcome in patients treated with the 
Resolute zotarolimus-eluting stent (R-ZES) and XIENCE V everolimus-eluting stent (EES).
methods:  Patients were randomly assigned to treatment with the R-ZES (n = 306) or the EES (n = 154). We assessed safety and efficacy 
outcomes at 4 years. The primary endpoint was target lesion failure (TLF), a composite of cardiac death, myocardial infarction not clearly 
attributable to non-target vessels, and clinically indicated target-vessel revascularization. Secondary endpoints were patient-oriented 
composite endpoint (POCE) including all-cause death, any myocardial infarction, and any revascularization. Predictors of TLF at 4 years 
were identified by Cox regression analysis.
Results:  At 4 years, the rates of target lesion failure (2.9% vs. 1.3%, p = 0.28), cardiac death (0% vs. 0.6%, p = 0.16), and target vessel 
myocardial infarction (0.7% vs. 0%, p = 0.31), clinically-indicated target vessel revascularization (TVR) (3.9% vs. 3.2%, p = 0.71), target 
lesion revascularization (2.6% vs. 0.6%, p = 0.15), definite/probable stent thrombosis (0.3% vs. 0.6%, p = 0.62), and POCE (5.2% vs. 
4.5%, p = 0.75) were similar with the R-ZES and EES. At multivariate Cox regression, diabetes (OR: 3.25, 95% CI: 0.99 to 10.64, p = 
0.048) only emerged as independent risk factor for 4-year TLF.
conclusion:  R-ZES and EES demonstrated similar safety and efficacy throughout 4 years.
